CaptnA,

I’m very sorry to hear this.

Her oncologists should know that CCR5 is upregulated in many metastatic tumors, but also that the tumor microenvironment is enhanced through increased expression of ccl5, causing trafficking of m2 monocytes and tregs, impairing the normal cytotoxic response to malignant cells.

Here are a few articles to share.

The CCL5/CCR5 Axis in Cancer Progression

https://res.mdpi.com/d_attachment/cancers/can...-01765.pdf

Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma

https://www.nature.com/articles/onc2016458

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer.

https://www.physiciansweekly.com/ccr5-is-a-pr...st-cancer/

Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

https://breast-cancer-research.biomedcentral....21-01391-1

CCR5 blockage by m********: a potential therapeutic option for metastatic breast cancer

https://pubmed.ncbi.nlm.nih.gov/30456574/

Leronlimab Continues to Demonstrate Early Promise in CCR5+ Metastatic TNBC

https://www.onclive.com/view/leronlimab-conti...tatic-tnbc